Zoetis Inc. (New York Stock Exchange:ZTS)
| Market Cap | 30.74B-50.9% |
| Revenue (ttm) | 9.52B+1.4% |
| Net Income | 2.62B+0.2% |
| EPS | 6.07+4.5% |
| Shares Out | 419.23M |
| PE Ratio | 12.06 |
| Forward PE | 11.34 |
| Dividend | $2.09(2.85%) |
| Ex-Dividend Date | Jul 20, 2026 |
| Volume | 5,441,829 |
| Open | 73.50 |
| Previous Close | 73.56 |
| Day's Range | 73.09 - 74.08 |
| 52-Week Range | 71.00 - 152.00 |
| Beta | 0.73 |
| Analysts | Hold |
| Price Target | 87.33(+19.12%) |
| Earnings Date | Nov 3, 2026 |
About ZTS
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
$ZTS stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of ZTS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | Jul 17, 2026 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Jul 16, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Jun 15, 2026 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Apr 13, 2026 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Mar 12, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Feb 10, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Dec 18, 2025 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Nov 17, 2025 |
Recently reported changes in ZTS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ZTS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ZTS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ZTS Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New ZTS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ZTS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ZTS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $928.97M |
| VOOVanguard S&P 500 ETF | $850.56M |
| VOVanguard Morningstar Mid-Cap ETF | $631.13M |
| IVViShares Core S&P 500 ETF | $418.23M |
| SPYState Street SPDR S&P 500 ETF | $379.00M |
| VTVVanguard Morningstar Value ETF | $277.99M |
Estimated from each fund’s disclosed top holdings × AUM
ZTS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ZTS’s recent data — informational, not investment advice
